tetano
Editor, Senior Moderator
J Infect Dis
. 2024 Jul 5:jiae342.
doi: 10.1093/infdis/jiae342. Online ahead of print. Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV
Nnenna Chime[SUP] 1 [/SUP], Bruno Anspach[SUP] 1 [/SUP], Vishal Jain[SUP] 1 [/SUP], Outi Laajalahti[SUP] 2 [/SUP], Thierry Ollinger[SUP] 3 [/SUP], Deborah Yaplee[SUP] 1 [/SUP], Joon Hyung Kim[SUP] 1 [/SUP]
Affiliations
Background: A single-dose investigational respiratory syncytial virus (RSV) vaccine, RSV prefusion protein F3 (RSVPreF3), was co-administered with a single-dose quadrivalent influenza vaccine (FLU-D-QIV) in a phase 3, randomized, controlled, multicenter study in healthy, non-pregnant women aged 18-49 years.
Methods: The study was observer-blind to evaluate the lot-to-lot consistency of RSVPreF3, and single-blind to evaluate the immune response, safety, and reactogenicity of RSVPreF3 co-administered with FLU-D-QIV.
Results: A total of 1415 participants were included in the per-protocol set. There was a robust immune response at day 31 across each of the 3 RSVPreF3 vaccine lots; adjusted geometric mean concentration ratios (95% confidence interval [CI]) were 1.01 (0.91, 1.12), 0.93 (0.84, 1.03), and 0.92 (0.83, 1.02) for RSV1/RSV2, RSV1/RSV3, and RSV2/RSV3, respectively. For FLU-D-QIV co-administered with RSVPreF3, versus FLU-D-QIV alone at day 31, noninferiority was satisfied for 3 of 4 strains assessed, with the lower limit of the 95% CI for geometric mean ratio >0.67.
Conclusions: Immunogenic consistency was demonstrated for 3 separate lots of RSVPreF3. Immunogenic noninferiority was demonstrated when comparing FLU-D-QIV administered alone, versus co-administered with RSVPreF3, for 3 strains of FLU-D-QIV. Co-administration was well tolerated, and both vaccines had clinically acceptable safety and reactogenicity profiles.
Clinical trials registration: NCT05045144; EudraCT, 2021-000357-26.
Keywords: RSVPreF3 vaccine; healthy women; immunogenicity; influenza virus; lot-to-lot consistency; quadrivalent influenza vaccine; reactogenicity; respiratory syncytial virus; safety; vaccine co-administration.
. 2024 Jul 5:jiae342.
doi: 10.1093/infdis/jiae342. Online ahead of print. Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV
Nnenna Chime[SUP] 1 [/SUP], Bruno Anspach[SUP] 1 [/SUP], Vishal Jain[SUP] 1 [/SUP], Outi Laajalahti[SUP] 2 [/SUP], Thierry Ollinger[SUP] 3 [/SUP], Deborah Yaplee[SUP] 1 [/SUP], Joon Hyung Kim[SUP] 1 [/SUP]
Affiliations
- PMID: 38970327
- DOI: 10.1093/infdis/jiae342
Background: A single-dose investigational respiratory syncytial virus (RSV) vaccine, RSV prefusion protein F3 (RSVPreF3), was co-administered with a single-dose quadrivalent influenza vaccine (FLU-D-QIV) in a phase 3, randomized, controlled, multicenter study in healthy, non-pregnant women aged 18-49 years.
Methods: The study was observer-blind to evaluate the lot-to-lot consistency of RSVPreF3, and single-blind to evaluate the immune response, safety, and reactogenicity of RSVPreF3 co-administered with FLU-D-QIV.
Results: A total of 1415 participants were included in the per-protocol set. There was a robust immune response at day 31 across each of the 3 RSVPreF3 vaccine lots; adjusted geometric mean concentration ratios (95% confidence interval [CI]) were 1.01 (0.91, 1.12), 0.93 (0.84, 1.03), and 0.92 (0.83, 1.02) for RSV1/RSV2, RSV1/RSV3, and RSV2/RSV3, respectively. For FLU-D-QIV co-administered with RSVPreF3, versus FLU-D-QIV alone at day 31, noninferiority was satisfied for 3 of 4 strains assessed, with the lower limit of the 95% CI for geometric mean ratio >0.67.
Conclusions: Immunogenic consistency was demonstrated for 3 separate lots of RSVPreF3. Immunogenic noninferiority was demonstrated when comparing FLU-D-QIV administered alone, versus co-administered with RSVPreF3, for 3 strains of FLU-D-QIV. Co-administration was well tolerated, and both vaccines had clinically acceptable safety and reactogenicity profiles.
Clinical trials registration: NCT05045144; EudraCT, 2021-000357-26.
Keywords: RSVPreF3 vaccine; healthy women; immunogenicity; influenza virus; lot-to-lot consistency; quadrivalent influenza vaccine; reactogenicity; respiratory syncytial virus; safety; vaccine co-administration.